Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.

Authors

Joann L Ater
Caihong Xia
Claire M Mazewski
Timothy N Booth
David R Freyer
Roger J Packer, George Washington UniversityFollow
Richard Sposto
Gilbert Vezina, George Washington UniversityFollow
Ian F Pollack

Document Type

Journal Article

Publication Date

6-15-2016

Journal

Cancer

Volume

122

Issue

12

Inclusive Pages

1928-1936

DOI

10.1002/cncr.29987

Keywords

Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschool; Female; Glioma; Humans; Male; Neurofibromatosis 1; Procarbazine; Thioguanine; Vincristine

APA Citation

Ater, J., Xia, C., Mazewski, C., Booth, T., Freyer, D., Packer, R., Sposto, R., Vezina, G., & Pollack, I. (2016). Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.. Cancer, 122 (12). http://dx.doi.org/10.1002/cncr.29987

Peer Reviewed

1